Bruker Corporation — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020. Bruker develops and sells scientific instruments and analytical and diagnostic solutions through its BSI Life Science, BSI NANO and BEST segments.
Key financial results
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Revenue | $424.0 million | $461.4 million |
| Gross profit / margin | $192.3 million / 45.4% | $214.7 million / 46.5% |
| Operating income / margin | $16.4 million / 3.9% | $41.9 million / 9.1% |
| Net income attributable to Bruker | $10.5 million | $30.8 million |
| Diluted EPS | $0.07 | $0.20 |
| Operating cash flow | $35.0 million | $14.2 million |
| Free cash flow | $4.5 million | $3.6 million |
- Revenue fell 8.1% year over year; organic revenue declined 7.9%. Acquisitions added approximately $4.3 million, while foreign currency translation reduced revenue by $5.5 million.
- Gross margin and operating margin contracted amid lower revenue, factory and operating inefficiencies, unfavorable mix, and COVID-19 disruptions. Reported non-GAAP gross margin was 46.7% versus 48.9%; non-GAAP operating margin was 7.6% versus 13.5%.
- Revenue by segment: BSI Life Science $261.4 million, down 5.3%; BSI NANO $120.1 million, down 14.7%; BEST $46.2 million, down 3.3%. NANO also faced weakened industrial-market demand; BEST cited slower superconductor demand late in the quarter.
- Cash, cash equivalents and short-term investments totaled $851.7 million at March 31, up from $684.9 million at year-end. Total debt was $1,010.6 million, up from $813.3 million, including $196.3 million drawn on the revolving facility. The company reported $515.2 million available across revolving lines, including the effect of letters of credit, and compliance with debt covenants.
- Investing cash outflow was $100.6 million, including $50.0 million of short-term investment purchases, $30.5 million of capital expenditures and $22.0 million for acquisitions. Capital spending included approximately $20.0 million for production-facility productivity and expansion.
Material changes and management commentary
- Management attributed the Q1 revenue decline primarily to COVID-19-related customer and operating disruptions; revenue in China fell 30% year over year. Customer closures, travel limits, delayed installations and shipments, and reduced-capacity production sites affected activity.
- Bruker expected the pandemic to have a significant negative impact on Q2 2020 results. It did not provide a clear quantified full-year outlook, citing uncertainty about the outbreak, restrictions and economic effects.
- Temporary cost actions included short-time work in many European operations, tiered salary reductions, brief closures at select sites, a hiring freeze and reduced discretionary spending. Management expected these measures to have a significant impact on the quarter ending June 30, 2020. It said supply and capacity would not be limiting in H2 if gradual reopening continued without renewed disruption.
- Contract liabilities rose to $342.1 million from $312.5 million, primarily due to installation delays associated with COVID-19. Remaining performance obligations were approximately $1.852 billion; about 54.2% was expected to be recognized within 12 months.
- Q1 included $6.2 million in other charges, including $3.4 million of investigation-related professional fees, $1.5 million of restructuring costs, $1.2 million of long-lived asset impairments and $0.9 million of IT transformation costs, partly offset by a $1.1 million acquisition-related benefit. No goodwill impairment was recorded following an interim COVID-related assessment.
Risks, contingencies and controls
- COVID-19 created substantial uncertainty around demand, customer and supplier operations, manufacturing, installations, travel, and the broader economy. Remote work also raised productivity and cybersecurity concerns.
- Disclosure controls were not effective at a reasonable assurance level because of material weaknesses in the control environment, income-tax controls and revenue-recognition controls at a U.S. subsidiary. Management stated the reported financial statements fairly presented the periods shown.
- Bruker was defending patent suits involving Luxendo and its timsTOF product line. It reported no material accruals for these matters and believed pending proceedings would not materially affect its financial statements.
- A Korean tender-bidding investigation remained pending, with a hearing rescheduled for May 29, 2020. A related three-month restriction on Bruker Korea’s sales to government entities ended March 27, 2020; such sales were less than 3% of 2019 company revenue.
Important facts for investors to verify
- Whether COVID-related customer closures, delayed installations and reduced production continued to weigh on Q2 revenue and margins, and how the cost actions affected results.
- Whether Bruker maintained adequate liquidity and covenant compliance as debt increased and the pandemic affected cash generation.
- Whether elevated inventory and contract liabilities converted into shipments, installations, recognized revenue and cash collections.
- Progress in remediating the disclosed material weaknesses in tax and revenue controls.
- Developments in the patent litigation and the pending Korean investigation, including any financial or operating consequences.